Trial Profile
Phase IIb study of SNJ-1656; A dose-response study in patients with primary open angle glaucoma or ocular hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Sep 2015
Price :
$35
*
At a glance
- Drugs Y 39983 (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Sponsors Senju Pharmaceutical
- 04 Sep 2015 New trial record